The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.
Neha Korde
No relevant relationships to disclose
Adriana Zingone
No relevant relationships to disclose
Mary Kwok
No relevant relationships to disclose
Elisabet E. Manasanch
No relevant relationships to disclose
Manisha Bhutani
No relevant relationships to disclose
Rene Costello
No relevant relationships to disclose
Mary Ann Yancey
No relevant relationships to disclose
Marcia Mulquin
No relevant relationships to disclose
Katherine R. Calvo
No relevant relationships to disclose
Irina Maric
No relevant relationships to disclose
Prashant Tembhare
No relevant relationships to disclose
Constance Yuan
No relevant relationships to disclose
Maryalice Stetler-Stevenson
No relevant relationships to disclose
Diane Carol Arthur
No relevant relationships to disclose
Peter L. Choyke
No relevant relationships to disclose
Karen A Kurdziel
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
Mark Raffeld
No relevant relationships to disclose
Mark J. Roschewski
No relevant relationships to disclose
Ola Landgren
No relevant relationships to disclose